Who
Isabel Kalofonos
Chief Commercial Officer
Company insider
Files Form 4 as: Chief Commercial Officer, CG Oncology; Chief Commercial Officer, Crinetics Pharmaceuticals; SVP & Chief Commercial Officer, ImmunoGen.
In numbers
- Trades disclosed
- 26
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $275K
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 28 Apr 2023
- Last trade
- 15 Oct 2026
- Last filed
- 19 Oct 2026
Companies traded
Activity over time
1 Jan – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Oct 2026filed 19 Oct 2026 | CGON CG Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —92,000 at $0.00 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code D | $142K1,669 at $85.00 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code D | $2.9M34,000 at $85.00 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $4.3M97,500 at $44.41 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $4.3M97,500 at $44.41 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $2.3M55,000 at $41.21 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $2.3M55,000 at $41.21 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code D | $142K1,669 at $85.00 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code D | $2.9M34,000 at $85.00 | filing |
| 23 Feb 2026filed 25 Feb 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —34,000 at $0.00 | filing |
| 23 Feb 2026filed 25 Feb 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
| 23 Feb 2026filed 25 Feb 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
| 23 Feb 2026filed 25 Feb 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —34,000 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $101K2,500 at $40.59 | filing |
| 5 Jan 2026filed 7 Jan 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $138K2,500 at $55.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $101K2,500 at $40.59 | filing |
| 5 Jan 2026filed 7 Jan 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $138K2,500 at $55.00 | filing |
| 10 Jan 2025filed 13 Jan 2025 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
News
CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officermanilatimes.net · 13 Oct 2026
1 headline in the last 90 days name Isabel Kalofonos; no company of theirs resolves to a name we track.